Stayble Therapeutics AB (publ) (STABL.ST)
SEK 0.45
(-5.88%)
SEK 0.45
(-5.88%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | -321.14 Thousand SEK | 0.0% |
| 2022 | - SEK | 0.0% |
| 2021 | - SEK | 0.0% |
| 2020 | - SEK | 100.0% |
| 2019 | -246.99 SEK | 99.91% |
| 2018 | -290.5 Thousand SEK | -7.87% |
| 2017 | -269.3 Thousand SEK | 24.14% |
| 2016 | -355 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 1.00 SEK | 100.0% |
| 2024 Q1 | -2.21 Million SEK | 0.0% |
| 2023 FY | - SEK | 0.0% |
| 2023 Q4 | - SEK | 0.0% |
| 2023 Q2 | -2780.00 SEK | 35.47% |
| 2023 Q1 | -4308.00 SEK | 0.0% |
| 2023 Q3 | - SEK | 100.0% |
| 2022 Q2 | -690 Thousand SEK | 0.0% |
| 2022 FY | - SEK | 0.0% |
| 2022 Q4 | - SEK | -100.0% |
| 2022 Q3 | 1000.00 SEK | 100.14% |
| 2022 Q1 | - SEK | 100.0% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 FY | - SEK | 0.0% |
| 2021 Q3 | -1000.00 SEK | 99.82% |
| 2021 Q4 | -524 Thousand SEK | -52300.0% |
| 2021 Q2 | -551 Thousand SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 FY | - SEK | 100.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 FY | -246.99 SEK | 99.91% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | -290.5 Thousand SEK | -7.87% |
| 2017 FY | -269.3 Thousand SEK | 24.14% |
| 2016 FY | -355 Thousand SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| NextCell Pharma AB | 545.23 Thousand SEK | 158.9% |
| Biovica International AB (publ) | 2.19 Million SEK | 114.604% |
| Abliva AB (publ) | - SEK | Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | -12745.8% |
| Aptahem AB (publ) | - SEK | Infinity% |
| Alligator Bioscience AB (publ) | 2.00 SEK | 16057350.0% |
| BioInvent International AB (publ) | 11.84 Million SEK | 102.711% |
| BioArctic AB (publ) | - SEK | Infinity% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 103.542% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 101.572% |
| Cantargia AB (publ) | - SEK | Infinity% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 107.961% |
| CombiGene AB (publ) | -1.79 Million SEK | 82.149% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | 145.878% |
| Fluicell AB (publ) | 3.15 Million SEK | 110.195% |
| Genovis AB (publ.) | 14.9 Million SEK | 102.155% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 103.28% |
| Mendus AB (publ) | - SEK | Infinity% |
| Karolinska Development AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | - SEK | Infinity% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | Infinity% |
| Saniona AB (publ) | 1.00 SEK | 32114600.0% |
| Spago Nanomedical AB (publ) | 1.00 SEK | 32114600.0% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 95.5% |
| Xintela AB (publ) | 398 Thousand SEK | 180.69% |
| Amniotics AB (publ) | 534 Thousand SEK | 160.14% |
| Corline Biomedical AB | -3.85 Million SEK | 91.674% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 28.153% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | Infinity% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | 32214.5% |
| Intervacc AB (publ) | 10.48 Million SEK | 103.063% |
| Kancera AB (publ) | -1950.00 SEK | -16368.974% |
| Lipum AB (publ) | - SEK | Infinity% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 80.249% |
| Nanologica AB (publ) | 2.97 Million SEK | 110.802% |
| Vicore Pharma Holding AB (publ) | - SEK | Infinity% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 100.301% |
| AcouSort AB (publ) | 2.08 Million SEK | 115.44% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 101.335% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | Infinity% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 100.912% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 100.734% |
| Simris Alg AB (publ) | 1.09 Million SEK | 129.436% |
| Ziccum AB (publ) | -4.18 Million SEK | 92.334% |
| SynAct Pharma AB | - SEK | Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 62.787% |
| Camurus AB (publ) | 100.95 Million SEK | 100.318% |
| 2cureX AB (publ) | -1000.00 SEK | -32014.5% |
| Asarina Pharma AB (publ) | - SEK | Infinity% |
| Isofol Medical AB (publ) | - SEK | Infinity% |
| I-Tech AB | 4.28 Million SEK | 107.503% |
| Cyxone AB (publ) | - SEK | Infinity% |
| Biosergen AB | -4.92 Million SEK | 93.485% |
| Annexin Pharmaceuticals AB (publ) | - SEK | Infinity% |
| Alzinova AB (publ) | -3.27 Million SEK | 90.203% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 113.243% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | -21511.373% |
| Pila Pharma AB (publ) | 1.00 SEK | 32114600.0% |
| Ascelia Pharma AB (publ) | - SEK | Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 131.24% |